Burhan Mohamedali, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1831393289
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,940 of the $154,228 with a category attached, or 64.2%. 50 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 31.2% of the total.
Across 1,383 payments — averaging $111.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$48K
- AstraZeneca$24K
- Boston Scientific$22K
- Novartis$16K
- Abbott$12K
- Kestra Medical Technology Services, Inc.$8K
- plus $23K from 44 others
Across 12 payments — averaging $1618.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$19K
What the payments were for
- Consulting fees$17,21811%
- Speaking & faculty fees$98,94064%
- Travel & lodging$2,6762%
- Food & beverage$34,94323%
- Education$4510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$45,794
- OPSUMIT$45,794
- FARXIGA$22,595
- ENTRESTO$14,417
- Watchman$14,064
- Assure WCD$8,087
- WATCHMAN Access System$4,273
- Kerendia$4,000
- CardioMEMS HF System$3,553
- Rapiblyk$2,774
- Accent Pacemaker$2,100
- GENERAL - THERAPIES$1,436
- Adempas$1,025
- OPTIMIZER$848
- Confirm Rx$825
- SAPIEN 3 Ultra RESILIA$722
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$703
- AVEIR$558
- Quadra Assura CRT Defibrillator$460
- FFRct$404
How this compares
$154,228 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 394 | $385,742 |
| OpsumitMacitentan | 24 | $302,714 |
| FarxigaDapagliflozin Propanediol | 380 | $294,199 |
| CamzyosMavacamten | 31 | $266,037 |
| EliquisApixaban | 185 | $210,407 |
| JardianceEmpagliflozin | 109 | $94,163 |
| XareltoRivaroxaban | 53 | $62,462 |
| DapagliflozinDapagliflozin Propanediol | 27 | $14,921 |
| BrilintaTicagrelor | 17 | $8,782 |
| Metoprolol Succinate | 289 | $4,490 |
| Ranolazine ErRanolazine | 32 | $3,566 |
| Bumetanide | 80 | $3,414 |
| Atorvastatin Calcium | 170 | $1,623 |
| Amlodipine Besylate | 208 | $1,452 |
| Nifedipine ErNifedipine | 48 | $1,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $16,028 | $385,742394 claims |
| AstraZenecaFarxiga, Brilinta | $23,917 | $302,980397 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $48,084 | $302,71424 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $726 | $266,03731 claims |
| PfizerEliquis | $1,602 | $210,407185 claims |
| Boehringer IngelheimJardiance | $437 | $94,163109 claims |
| Johnson & JohnsonXarelto | $1,259 | $62,46253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Hirsch MehtaSan Diego$494K
- Marcus UreySan Diego$341K
- Barry GreenbergSan Diego$270K
- Brian JaskiSan Diego$235K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Hao TranSan Diego$147K
- Justin ParizoSan Diego$24K
- Eric AdlerSan Diego$24K
- Peter HoaglandSan Diego$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.